Clinical Trial

Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-03.
Trial Details
NCT Number NCT07285265
Lead Sponsor Suzhou Abogen Biosciences Co., Ltd.
Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions Varicella-zoster Virus
Enrollment 180 participants
Start Date 2025-05-27
Primary Completion 2025-11-06 (estimated)
Study Completion 2026-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-11